Skip to content

5-MeO-DMT: all studies

Page 42 of 112: studies 411 to 420 of 1,115, newest first. Back to the 5-MeO-DMT overview

Research

Policy Considerations for Psychedelics in Research and Medicine – What’s Next on the Schedule?

Journal of Science Policy & Governance July 2, 2026 Matthew A. Boehm, Oriana Mayorga

There is growing interest in psychedelic compounds such as psilocybin, 3,4-metheylenedioxymethamphetamine (MDMA), lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT) given emerging research on potential uses as treatments for a variety of health conditions. The United States Food and Drug Administration (FDA) has granted multiple “Breakthrough Therapy” designations to various...

[Illicit use of classic psychedelics and suicidality: A systematic literature review].

L'Encephale July 1, 2026 Ana Beatriz Pereira de Oliveira, Matthieu Hein

INTRODUCTION Given the contrasting results available in the literature, the objective of this systematic review was to investigate the specific impact of illicit use of classic psychedelics (psilocybin, LSD, DMT, mescaline) on suicidality (suicidal ideation, suicide planning, suicide attempts, suicides). METHOD According to PRISMA criteria, a systematic review of the literature was carried out...

5-HT2A receptors in the prelimbic cortex VIP-expressing interneurons: A mechanism for psychedelic-induced innate fear attenuation.

British Journal of Pharmacology July 1, 2026 Yuanyuan Wang, Yishan Yao, Ruibin Su et al. 1 citation

Fear-related psychiatric disorders such as phobias and anxiety are insufficiently treated by current therapies. Psychedelics targeting 5-HT₂A receptors show promise in modulating fear circuits, but their specific neurobiological substrates remain unclear. This study investigates the effects of 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT), a psychedelic compound, on innate fear responses and...

DOI: 10.1111/bph.70307 (opens in new tab) Full text (opens in new tab) 4‐Aco‐DMT Innate fear Psychedelics Trimethylthiazoline +1

Registered Clinical Trials of Ayahuasca and DMT: A Scoping Review.

Clinical Pharmacology & Therapeutics July 1, 2026 Tijana Stojanovic, Kent W Nilsson, Robert Fredriksson et al.

Interest in ayahuasca and its main component, N,N-Dimethyltryptamine (DMT), has currently moved from historical and experimental use into modern clinical development. Yet, current evidence is fragmented, and systematic mapping of trial methods and design choices remains limited. We therefore systematically examined registered interventional trials of DMT, ayahuasca, and DMT combined with...

Single Ayahuasca administration attenuates alcohol relapse and associated behavioral, neurochemical, and oxidative alterations in rats

Progress in Neuro-Psychopharmacology and Biological Psychiatry July 1, 2026 Guilherme Lodetti, Rafael Mariano de Bitencourt, Antonio Inserra et al.

BackgroundAlcohol use disorder (AUD) remains difficult to treat with lasting success, leading to growing interest in alternative therapeutic approaches. Psychedelic compounds such as Ayahuasca, a traditional brew used in Indigenous Amazonian ceremonies containing N,N-dimethyltryptamine (DMT) along with monoamine oxidase-inhibiting β-carbolines, have shown promise in reducing addictive...

DOI: 10.1016/j.pnpbp.2026.111817 (opens in new tab) Ayahuasca Serotonin Oxidative stress Glutathione peroxidase +12

Neuroestimulantes naturales: de rituales ancestrales a terapias de vanguardia

Revista CienciaUANL July 1, 2026 Armando Ordaz‐hernández, M. Corona-Ramírez, Israel Jesús Orlando Guerrero

La psilocibina, presente en los “hongos mágicos”, y la 5-MeO-DMT, secretada por el sapo Incilius alvarius, fueron empleadas ancestralmente en rituales espirituales en México. Hoy, la ciencia las reconoce como terapias prometedoras contra depresión, ansiedad, estrés postraumático y adicciones resistentes a tratamientos convencionales. Actúan sobre receptores de serotonina y estimulan la...

DOI: 10.29105/cienciauanl29.138-5 (opens in new tab) Addiction Mental health Clinical practice Psychotherapist

Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats.

Pharmacology, Biochemistry, and Behavior June 30, 2026 Lucie Ladislavová, Viera Kútna, Kristýna Mazochová et al.

Psilocin (4-hydroxy-N, N-dimethyltryptamine) is a substituted tryptamine alkaloid and a nonselective serotonergic agonist acting predominantly at 5-HT2A/C receptors, with substantial binding to 5-HT1A and 5-HT2B receptors. Microdosing is the practice of taking a very small, sub-perceptual dose, typically 5% to 10% of a full recreational dose, to improve mood, creativity, and focus without...

Vaporized mebufotenin leads to improvement in treatment‐resistant depression

The Brown University Psychopharmacology Update June 28, 2026

An individualized one‐day dosing regimen of a vaporized formulation of the psychedelic mebufotenin (5‐methoxy‐ N,N ‐dimethyltryptamine; 5‐MeO‐DMT) was more effective than placebo in improving depressive symptoms in adults with treatment‐resistant depression, a Phase 2b trial has found. No serious treatment‐emergent adverse events were reported during the 7‐day study. Results were published...

DOI: 10.1002/pu.31471 (opens in new tab) Anxiety Depression economics Adverse effect Dosing +5

Short- and Long-Acting Psychedelics: Structure-Activity Relationships, Pharmacology, and Implications for Neuropsychiatric Therapeutics.

ACS Chemical Neuroscience June 17, 2026 Anoushka Bhat, Elmira Zolali, Mahfuz A Sakib et al.

Psychedelics have re-emerged as promising therapeutics for neuropsychiatric disorders, including depression, anxiety, post-traumatic stress disorder, and substance use disorders. While their beneficial effects are largely attributed to serotonin 2A (5-HT2A) receptor activation, psychedelics exhibit substantial diversity in chemical structure, receptor binding kinetics, metabolism, and duration...

Anxiety-related platform in zebrafish (Danio rerio) larvae: An integrated analysis of behavioural and molecular assay in drug screening research

Biomedicine & Pharmacotherapy June 17, 2026 Małgorzata Potoczna, Natalia Kasica, Małgorzata Chmielewska-Krzesińska et al.

Zebrafish larvae are increasingly used in behavioural pharmacology because of their translational relevance and suitability for anxiety- and stress-related studies. However, it remains unclear whether commonly used behavioural assays and molecular stress markers provide convergent evidence of anxiolytic-like drug activity. This study therefore aimed not to validate a single predictive screening...

DOI: 10.1016/j.biopha.2026.119680 (opens in new tab) Zebrafish Drug discovery Screening techniques Phenotypic screening +4